Top

Published in:

Open Access 01-06-2012 | Original Paper

Genomic aberrations relate early and advanced stage ovarian cancer

Authors: Afra Zaal, Wouter J. Peyrot, P. M. J. J. Berns, Maria E. L. van der Burg, Jan H. W. Veerbeek, J. Baptist Trimbos, Isabelle Cadron, Paul J. van Diest, Wessel N. van Wieringen, Oscar Krijgsman, Gerrit A. Meijer, Jurgen M. J. Piek, Petra J. Timmers, Ignace Vergote, René H. M. Verheijen, Bauke Ylstra, Ronald P. Zweemer, On behalf of the EORTC GCG Translational Research Group

Published in: Cellular Oncology | Issue 3/2012

Abstract

Background

Because of the distinct clinical presentation of early and advanced stage ovarian cancer, we aim to clarify whether these disease entities are solely separated by time of diagnosis or whether they arise from distinct molecular events.

Methods

Sixteen early and sixteen advanced stage ovarian carcinomas, matched for histological subtype and differentiation grade, were included. Genomic aberrations were compared for each early and advanced stage ovarian cancer by array comparative genomic hybridization. To study how the aberrations correlate to the clinical characteristics of the tumors we clustered tumors based on the genomic aberrations.

Results

The genomic aberration patterns in advanced stage cancer equalled those in early stage, but were more frequent in advanced stage (p = 0.012). Unsupervised clustering based on genomic aberrations yielded two clusters that significantly discriminated early from advanced stage (p = 0.001), and that did differ significantly in survival (p = 0.002). These clusters however did give a more accurate prognosis than histological subtype or differentiation grade.

Conclusion

This study indicates that advanced stage ovarian cancer either progresses from early stage or from a common precursor lesion but that they do not arise from distinct carcinogenic molecular events. Furthermore, we show that array comparative genomic hybridization has the potential to identify clinically distinct patients.

Available only for authorised users

M. Akeson, A.M. Jakobsen, B.M. Zetterqvist, E. Holmberg, M. Brannstrom, G. Horvath, A population-based 5-year cohort study including all cases of epithelial ovarian cancer in western Sweden: 10-year survival and prognostic factors. Int. J. Gynecol. Cancer 19, 116–123 (2009)PubMedCrossRef

M. Choi, C.D. Fuller, C.R. Thomas Jr., S.J. Wang, Conditional survival in ovarian cancer: results from the SEER dataset 1988–2001. Gynecol. Oncol. 109, 203–209 (2008)PubMedCrossRef

B. Aunoble, R. Sanches, E. Didier, Y.J. Bignon, Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer (review). Int. J. Oncol. 16, 567–576 (2000)PubMed

S. Hauptmann, C. Denkert, I. Koch, S. Petersen, K. Schluns, A. Reles, M. Dietel, I. Petersen, Genetic alterations in epithelial ovarian tumors analyzed by comparative genomic hybridization. Hum. Pathol. 33, 632–641 (2002)PubMedCrossRef

J.M. Piek, P. Kenemans, R.H. Verheijen, Intraperitoneal serous adenocarcinoma: a critical appraisal of three hypotheses on its cause. Am. J. Obstet. Gynecol. 191, 718–732 (2004)PubMedCrossRef

V. Shridhar, J. Lee, A. Pandita, S. Iturria, R. Avula, J. Staub, M. Morrissey, E. Calhoun, A. Sen, K. Kalli, G. Keeney, P. Roche, W. Cliby, K. Lu, R. Schmandt, G.B. Mills, R.C. Bast Jr., C.D. James, F.J. Couch, L.C. Hartmann, J. Lillie, D.I. Smith, Genetic analysis of early- versus late-stage ovarian tumors. Cancer Res. 61, 5895–5904 (2001)PubMed

R.P. Brosens, J.C. Haan, B. Carvalho, F. Rustenburg, H. Grabsch, P. Quirke, A.F. Engel, M.A. Cuesta, N. Maughan, M. Flens, G.A. Meijer, B. Ylstra, Candidate driver genes in focal chromosomal aberrations of stage II colon cancer. J. Pathol. 221, 411–424 (2010)PubMed

S.J. Smeets, U. Harjes, W.N. van Wieringen, D. Sie, R.H. Brakenhoff, G.A. Meijer, B. Ylstra, To DNA or not to DNA? That is the question, when it comes to molecular subtyping for the clinic! Clin Cancer Res (2011)

J.B. Trimbos, I. Vergote, G. Bolis, J.B. Vermorken, C. Mangioni, C. Madronal, M. Franchi, S. Tateo, G. Zanetta, G. Scarfone, L. Giurgea, P. Timmers, C. Coens, S. Pecorelli, Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J. Natl Cancer Inst. 95, 113–125 (2003)PubMedCrossRef

10.

B. Trimbos, P. Timmers, S. Pecorelli, C. Coens, K. Ven, B.M. van der, A. Casado, Surgical staging and treatment of early ovarian cancer: Long-term analysis from a randomized trial. J Natl Cancer Inst (2010)

11.

L. Verleye, P.B. Ottevanger, G.B. Kristensen, T. Ehlen, N. Johnson, M.E. van der Burg, N.S. Reed, R.H. Verheijen, K.N. Gaarenstroom, B. Mosgaard, J.M. Seoane, d. van, V, R. Lotocki, G.W. van der, B. Penninckx, C. Coens, G. Stuart, I. Vergote, Quality of pathology reports for advanced ovarian cancer: Are we missing essential information? An audit of 479 pathology reports from the EORTC-GCG 55971/NCIC-CTG OV13 neoadjuvant trial. Eur J Cancer (2010)

12.

M.M. Weiss, M.A. Hermsen, G.A. Meijer, N.C. van Grieken, J.P. Baak, E.J. Kuipers, P.J. van Diest, Comparative genomic hybridisation. Mol. Pathol. 52, 243–251 (1999)PubMedCrossRef

13.

T.E. Buffart, D. Israeli, M. Tijssen, S.J. Vosse, A. Mrsic, G.A. Meijer, B. Ylstra, Across array comparative genomic hybridization: a strategy to reduce reference channel hybridizations. Genes Chromosomes Cancer 47, 994–1004 (2008)PubMedCrossRef

14.

T.E. Buffart, M. Tijssen, T. Krugers, B. Carvalho, S.J. Smeets, R.H. Brakenhoff, H. Grabsch, G.A. Meijer, H.B. Sadowski, B. Ylstra, DNA quality assessment for array CGH by isothermal whole genome amplification. Cell. Oncol. 29, 351–359 (2007)PubMed

15.

M.A. van de Wiel, R. Brosens, P.H. Eilers, C. Kumps, G.A. Meijer, B. Menten, E. Sistermans, F. Speleman, M.E. Timmerman, B. Ylstra, Smoothing waves in array CGH tumor profiles. Bioinformatics 25, 1099–1104 (2009)PubMedCrossRef

16.

M.A. van de Wiel, K.I. Kim, S.J. Vosse, W.N. van Wieringen, S.M. Wilting, B. Ylstra, CGHcall: calling aberrations for array CGH tumor profiles. Bioinformatics 23, 892–894 (2007)PubMedCrossRef

17.

A.B. Olshen, E.S. Venkatraman, R. Lucito, M. Wigler, Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 5, 557–572 (2004)PubMedCrossRef

18.

M.A. van de Wiel, W.N. van Wieringen, CGHregions: dimension reduction for array CGH data with minimal information loss. Cancer Informat. 3, 55–63 (2007)

19.

M.A. van de Wiel, S.J. Smeets, R.H. Brakenhoff, B. Ylstra, CGHMultiArray: exact P-values for multi-array comparative genomic hybridization data. Bioinformatics 21, 3193–3194 (2005)PubMedCrossRef

20.

I. Scheinin, J.A. Ferreira, S. Knuutila, G.A. Meijer, M.A. van de Wiel, B. Ylstra, CGHpower: exploring sample size calculations for chromosomal copy number experiments. BMC Bioinforma. 11, 331 (2010)CrossRef

21.

S.M. Wilting, S.J. Smeets, P.J. Snijders, W.N. van Wieringen, M.A. van de Wiel, G.A. Meijer, B. Ylstra, C.R. Leemans, C.J. Meijer, R.H. Brakenhoff, B.J. Braakhuis, R.D. Steenbergen, Genomic profiling identifies common HPV-associated chromosomal alterations in squamous cell carcinomas of cervix and head and neck1. BMC Med. Genom. 2, 32 (2009)CrossRef

22.

W.N. van Wieringen, M.A. van de Wiel, B. Ylstra, Weighted clustering of called array CGH data. Biostatistics 9, 484–500 (2008)PubMedCrossRef

23.

R Development Core Team, R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. Ref Type: Generic (2009)

24.

J.P. Geisler, M.J. Goodheart, A.K. Sood, R.J. Holmes, M.A. Hatterman-Zogg, R.E. Buller, Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma. Cancer 98, 2199–2206 (2003)PubMedCrossRef

25.

J. Helleman, I. van Staveren, W.N. Dinjens, P.F. van Kuijk, K. Ritstier, P.C. Ewing, M.E. van der Burg, G. Stoter, E.M. Berns, Mismatch repair and treatment resistance in ovarian cancer. BMC Cancer 6, 201 (2006)PubMedCrossRef

26.

J. Plisiecka-Halasa, A. nsonka-Mieszkowska, E. Kraszewska, A. nska-Bidzinska, J. Kupryjanczyk, Loss of heterozygosity, microsatellite instability and TP53 gene status in ovarian carcinomas. Anticancer Res. 28, 989–996 (2008)PubMed

27.

I.M. Shih, R.J. Kurman, Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am. J. Pathol. 164, 1511–1518 (2004)PubMedCrossRef

Title: Genomic aberrations relate early and advanced stage ovarian cancer
Authors: Afra Zaal
Wouter J. Peyrot
P. M. J. J. Berns
Maria E. L. van der Burg
Jan H. W. Veerbeek
J. Baptist Trimbos
Isabelle Cadron
Paul J. van Diest
Wessel N. van Wieringen
Oscar Krijgsman
Gerrit A. Meijer
Jurgen M. J. Piek
Petra J. Timmers
Ignace Vergote
René H. M. Verheijen
Bauke Ylstra
Ronald P. Zweemer
On behalf of the EORTC GCG Translational Research Group
Publication date: 01-06-2012
Publisher: Springer Netherlands
Published in: Cellular Oncology / Issue 3/2012
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI: https://doi.org/10.1007/s13402-012-0077-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2012

Erratum to: The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer

Cell culture models for studying the development of Barrett’s esophagus: a systematic review

Galectin-3 genetic variants are associated with platinum-based chemotherapy response and prognosis in patients with NSCLC

New insights and clinical advancements in cellular oncology

Alterations of monocarboxylate transporter densities during hypoxia in brain and breast tumour cells

High HSP27 and HSP70 expression levels are independent adverse prognostic factors in primary resected colon cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer